Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $607 | $415 | $352 | $413 |
| - Cash | $36 | $26 | $31 | $109 |
| + Debt | $1 | $9 | $2 | $3 |
| Enterprise Value | $572 | $397 | $323 | $307 |
| Revenue | $6 | $18 | $39 | $11 |
| % Growth | -66% | -53.5% | 255.1% | – |
| Gross Profit | $6 | $18 | $39 | $11 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$68 | -$71 | -$62 | -$72 |
| % Margin | -1,108.5% | -391.3% | -158.5% | -652% |
| Net Income | -$70 | -$73 | -$69 | -$76 |
| % Margin | -1,133% | -401.6% | -178% | -693.9% |
| EPS Diluted | -0.38 | -0.44 | -0.46 | -0.73 |
| % Growth | 13.6% | 4.3% | 37% | – |
| Operating Cash Flow | -$65 | -$86 | -$35 | -$68 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$65 | -$87 | -$36 | -$68 |